209 related articles for article (PubMed ID: 12557289)
1. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis.
Villar LM; Masjuan J; González-Porqué P; Plaza J; Sádaba MC; Roldán E; Bootello A; Alvarez-Cermeño JC
Ann Neurol; 2003 Feb; 53(2):222-6. PubMed ID: 12557289
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
[TBL] [Abstract][Full Text] [Related]
3. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
5. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
Sola P; Mandrioli J; Simone AM; Ferraro D; Bedin R; Annecca R; Venneri MG; Nichelli PF; Merelli E
Mult Scler; 2011 Mar; 17(3):303-11. PubMed ID: 21078694
[TBL] [Abstract][Full Text] [Related]
6. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.
Thangarajh M; Gomez-Rial J; Hedström AK; Hillert J; Alvarez-Cermeño JC; Masterman T; Villar LM
Mult Scler; 2008 Nov; 14(9):1208-13. PubMed ID: 18755821
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
9. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
Villar LM; Masjuan J; González-Porqué P; Plaza J; Sádaba MC; Roldán E; Bootello A; Alvarez-Cermeño JC
Neurology; 2002 Aug; 59(4):555-9. PubMed ID: 12196648
[TBL] [Abstract][Full Text] [Related]
11. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
12. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
14. [Late onset multiple sclerosis].
Delalande S; De Seze J; Ferriby D; Stojkovic T; Vermersch P
Rev Neurol (Paris); 2002 Nov; 158(11):1082-7. PubMed ID: 12451340
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
17. The natural history of primary progressive MS in British Columbia, Canada.
Tremlett H; Paty D; Devonshire V
Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
[TBL] [Abstract][Full Text] [Related]
18. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
[TBL] [Abstract][Full Text] [Related]
19. The natural history of primary progressive multiple sclerosis.
Koch M; Kingwell E; Rieckmann P; Tremlett H
Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.
Villar LM; Sádaba MC; Roldán E; Masjuan J; González-Porqué P; Villarrubia N; Espiño M; García-Trujillo JA; Bootello A; Alvarez-Cermeño JC
J Clin Invest; 2005 Jan; 115(1):187-94. PubMed ID: 15630459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]